PDCD1 and neoplasm: After combined therapy, tumour antigen-specific CD8+ T cells that were fully stimulated in the injected lesion can traffic and infiltrate distant metastatic lesions to exert systemic anti-tumour activity, thereby reversing primary resistance to PD-1 blockade therapy [28].